Cero Therapeutics Holdings Inc. recently faced a potential delisting from The Nasdaq Capital Market due to its common stock trading below the minimum required bid price of $1.00 per share for a 30-day period ending on June 9, 2025. However, after appealing the delisting decision, the company successfully regained compliance with Nasdaq's listing requirements by July 7, 2025. As a result, the planned delisting hearing was canceled, and Cero Therapeutics' stock will continue to be listed and traded on the Nasdaq Capital Market.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cero Therapeutics Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-061911), on July 08, 2025, and is solely responsible for the information contained therein.